Disitamab vedotin (RC48)
爱地希(RC48)
A Chinese-developed HER2 antibody-drug conjugate (RemeGen).
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2021, ); NRDL (2022)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
HER2-expressing urothelial (bladder) cancer; HER2-positive gastric cancer.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Disitamab vedotin (RC48). Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.